2012 EDUCATIONAL BOOK - American Society of Clinical Oncology

41. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in
combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;
27:4733-4740.
42. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent
bevacizumab followed by bevacizumab plus irinotecan at tumor progression
in recurrent glioblastoma. J Clin Oncol. 2009;27:740-745.
43. Kamoun WS, Ley CD, Farrar CT, et al. Edema control by cediranib, a
vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs
survival despite persistent brain tumor growth in mice. J Clin Oncol.
2009;27:2542-2552.
44. Pope WB, Lai A, Nghiemphu P, et al. MRI in patients with high-grade
gliomas treated with bevacizumab and chemotherapy. Neurology. 2006;66:
1258-1260.
45. Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after
short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer
Cell. 2009;15:232-239.
46. Keunen O, Johansson M, Oudin A, et al. Anti-VEGF treatment reduces
blood supply and increases tumor cell invasion in glioblastoma. Proc Natl
Acad Sci USA.2011;108:3749-3754.
47. Lamszus K, Kunkel P, Westphal M. Invasion as limitation to antiangiogenic
glioma therapy. Acta Neurochir Suppl. 2003;88:169-177.
48. Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits
malignant progression of tumors to increased local invasion and distant
metastasis. Cancer Cell. 2009;15:220-231.
124
NORDEN, POPE, AND CHANG
49. Fischer I, Cunliffe CH, Bollo RJ, et al. High-grade glioma before and
after treatment with radiation and Avastin: initial observations. Neuro Oncol.
2008;10:700-708.
50. Iwamoto FM, Abrey LE, Beal K, et al. Patterns of relapse and prognosis
after bevacizumab failure in recurrent glioblastoma. Neurology. 2009;73:
1200-1206.
51. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent
malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology.
2008;70:779-787.
52. Narayana A, Kunnakkat SD, Medabalmi P, et al. Change in pattern of
relapse after antiangiogenic therapy in high-grade glioma. Int J Radiat Oncol
Biol Phys. 2012;82:77-82.
53. de Groot JF, Fuller G, Kumar AJ, et al. Tumor invasion after treatment
of glioblastoma with bevacizumab: radiographic and pathologic correlation in
humans and mice. Neuro Oncol. 2010;12:233-242.
54. Wick A, Dörner N, Schäfer N, et al. Bevacizumab does not increase the
risk of remote relapse in malignant glioma. Ann Neurol. 2011;69:586-592.
55. Pope WB, Xia Q, Paton VE, et al. Patterns of progression in patients
with recurrent glioblastoma treated with bevacizumab. Neurology. 2011;76:
432-437.
56. Chamberlain MC. Radiographic patterns of relapse in glioblastoma.
J Neurooncol. 2011;101:319-323.
57. Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma.
Neurology. 1980;30:907-911.